Free Trial
NASDAQ:THTX

Theratechnologies Q2 2025 Earnings Report

Theratechnologies logo
$3.16 +0.02 (+0.48%)
As of 11:33 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Theratechnologies EPS Results

Actual EPS
-$0.09
Consensus EPS
-$0.01
Beat/Miss
Missed by -$0.08
One Year Ago EPS
N/A

Theratechnologies Revenue Results

Actual Revenue
$17,729.00 billion
Expected Revenue
$24.30 million
Beat/Miss
Beat by +$17,728.98 billion
YoY Revenue Growth
N/A

Theratechnologies Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Wednesday, July 9, 2025
Conference Call Time
8:30AM ET

Earnings Documents

Theratechnologies Earnings Headlines

Elon’s BIGGEST warning yet?
Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.
Theratechnologies Inc. (THTX) - Yahoo Finance
See More Theratechnologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Theratechnologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Theratechnologies and other key companies, straight to your email.

About Theratechnologies

Theratechnologies (NASDAQ:THTX) is a specialty biopharmaceutical company focused on the development and commercialization of innovative therapies for people with metabolic and endocrine disorders. Founded in 1996 and headquartered in Montreal, Canada, the company operates under the ticker NASDAQ:THTX and TSX:TH and has established itself through targeted research in hormone regulation and metabolic control.

The company’s lead product, EGRIFTA (tesamorelin for injection), is an FDA-approved growth hormone-releasing factor analog indicated for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. In addition to its marketed therapy, Theratechnologies maintains a diversified pipeline with clinical programs such as Tesomet, an investigational drug for hypothalamic obesity and rare metabolic disorders, and ongoing research into novel small molecules aimed at improving lipid and glucose metabolism.

Theratechnologies manages a hybrid operating model combining in-house expertise in clinical development, regulatory affairs and commercial operations with strategic partnerships to expand its reach. The company markets EGRIFTA in the United States and Canada, while collaborating with regional partners in Europe and Latin America to obtain regulatory approvals and facilitate patient access. Manufacturing and distribution agreements ensure consistent supply through specialty pharmacies and hospital networks.

Governed by an experienced leadership team, Theratechnologies is led by President and CEO Michel Ménard, who brings over two decades of pharmaceutical and biotechnology experience. The executive team and board of directors include industry veterans with backgrounds in endocrinology, regulatory strategy and global commercialization, underscoring the company’s commitment to advancing care for patients with complex metabolic needs.

View Theratechnologies Profile

More Earnings Resources from MarketBeat